Around 147 million people, 2.5% of the world's population, use cannabis (annual prevalence), compared to 0.2% use cocaine and 0.2% use opiates. Cannabis is by far the most cultivated illicit drug, trafficked and abused. Half of all drug seizures worldwide. The geographical distribution of these seizures is also global and covers virtually every country in the world.
Some 147 million people, 2.5% of the world's population, use cannabis (annual prevalence), compared to 0.2% for cocaine and 0.2% for opiates. In the current decade, the abuse of cannabis has grown more rapidly than the abuse of cocaine and opiates. The most rapid increase in cannabis abuse since the 1960s has occurred in developed countries in North America, Western Europe and Australia. Cannabis has been increasingly linked to youth culture and the starting age is often lower than that of other drugs.
An analysis of cannabis markets shows that low prices match high levels of abuse, and vice versa. Cannabis appears to be not elastic in terms of prices in the short term, but rather elastic in the long term. While the number of cannabis users is greater than that of opioid and cocaine users, the lower prices of cannabis mean that, in economic terms, the cannabis market is much smaller than the market for opiates or cocaine. The Honourable Jody Wilson-Raybould, Minister of Justice and Attorney General of Canada, attaches the final report of the Working Group on the Legalization and Regulation of Cannabis.
Cannabis legislation and regulation is a complex task. This document provides a framework for organizing approaches to thinking about cannabis regimens when considering psychoactive products, alcohol analogs, tobacco and natural health products. Understanding the characteristics and semantic spaces that have been applied in the development of regimes to control currently legal psychoactive products can be instructive in rationalizing and organizing dialogue related to the legalization of psychoactive cannabis. Research funding is another key obstacle; without adequate financial support, cannabis research will not be able to inform health care or public health practice or keep up with changes in cannabis policy and cannabis use patterns.
A systematic review of published trials on the use of medicinal cannabinoids over a 40-year period was conducted to quantify the adverse effects of this therapy. Cannabis sativa is a plant that is used for its psychoactive and therapeutic effects and, like all psychoactive and therapeutic substances, it carries certain risks to human health. Governments should also encourage advice that grants cannabis research to give priority to cannabis research and encourage the academic and private sectors to contribute to funding. The Canadian Community Health Survey indicates that the smoking rate among cannabis users is more than double that of those who do not use cannabis.
For example, a decision could be made to take the same approach with any of the 10 forms of cannabis when dealing with people in a similar age category. As a result, research on the health effects of cannabis and cannabinoids has been limited in the United States, leaving patients, health professionals and policymakers without the evidence they need to make wise decisions regarding the use of cannabis and cannabinoids. It is common to draw analogies between alcohol and cannabis, especially when less restrictive political positions on cannabis are proposed during public discussions about legalization or decriminalization. Medical cannabis in patients with multiple sclerosis or disorders related to motor neurons was investigated in 25 eligible publications.
Since the legalization of cannabis, the states of Colorado and Washington have experienced sustained growth in their grocery cannabis markets. The Federation of Municipalities of Canada recommended that all retailers who distribute cannabis have a license similar to that of producers. Canada is in the fortunate position of having laboratory standards for cannabis as part of the existing medical cannabis program; as noted in Chapter 3, the capacity of this system must be adapted to a new regulatory environment and improved so that authorized producers can comply with the new ones products: safety and quality. and labeling requirements.
The Working Group also heard indigenous leaders and organizations talk about their interest in participating in the next cannabis market and about economic opportunities that can contribute to the creation of new jobs in their communities. Participants and the Working Group generally agreed that setting too high a level for legal access could have a number of unintended consequences, such as leading those consumers to continue buying cannabis on the illicit market. Legislation governing the use of medical cannabis continues to evolve rapidly, requiring pharmacists and other doctors to be aware of new or changing state regulations and institutional implications. .